You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 34 No. 7, July 1977 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (39)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Baclofen, A New Antispastic Drug

A Controlled, Multicenter Trial in Patients With Multiple Sclerosis

Barry A. Sachais, PhD; James N. Logue, MPH; Michael S. Carey, MD

Arch Neurol. 1977;34(7):422-428.


Abstract

• A double-blind, five-week, multicenter trial was conducted to compare the effect of baclofen, a unique amino acid derivative, with that of placebo in the treatment of 106 patients with spasticity secondary to multiple sclerosis. A spasticity assessment method that included a neurological examination, physicians' clinical impressions of changes during treatment, and a patient's self-evaluation was used to determine efficacy. This method showed baclofen (70 to 80 mg daily maximum, titrated) is effective relative to placebo in relieving symptoms of spasticity, such as flexor spasms, pain and stiffness, resistance to passive joint movements, and tendon stretch reflexes. Patient self-evaluation results also showed a significant reduction in clonus. Side effects were generally mild and transient.



Author Affiliations

From the Medical Department, Pharmaceuticals Division, CIBA-GEIGY Corp, Summit, NJ.


Footnotes

Accepted for publication Jan 31, 1977.

Reprint requests to Medical Department, CIBA-GEIGY Corp, Summit, NJ 07901 (Dr Sachais).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Facilitation of triceps brachii muscle contraction by tendon vibration after chronic cervical spinal cord injury
Ribot-Ciscar et al.
J. Appl. Physiol. 2003;94:2358-2367.
ABSTRACT | FULL TEXT  

Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients
Nielsen et al.
Mult Scler 2000;6:105-114.
ABSTRACT  

Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study
Nielsen et al.
Mult Scler 1996;2:227-232.
ABSTRACT  

Periodic Sharp Waves in Baclofen-Induced Encephalopathy
Hormes et al.
Arch Neurol 1988;45:814-815.
ABSTRACT  

Aggravated CNS Depression With Urinary Retention Secondary to Baclofen Administration
White
Arch Intern Med 1985;145:1717-1718.
ABSTRACT  

Baclofen in Trigeminal Neuralgia Its Effect on the Spinal Trigeminal Nucleus: A Pilot Study
Fromm et al.
Arch Neurol 1980;37:768-771.
ABSTRACT  

Phenytoin and Chlorpromazine in the Treatment of Spasticity
Cohan et al.
Arch Neurol 1980;37:360-364.
ABSTRACT  

Trial of Baclofen in Amyotrophic Lateral Sclerosis
Norris et al.
Arch Neurol 1979;36:715-716.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1977 American Medical Association. All Rights Reserved.